000			05769cam a2200421Ii 4500
001			95710
003			ES-MaUEC
005			20230102112718.0
006			m o d
007			cr cnu|||unuuu
008			170403t20172017sz a ob 001 0 eng d
020			_a3319437739 _q(electronic bk.)
020			_a9783319437736 _q(electronic bk.)
020			_z3319437712
020			_z9783319437712
040			_aN$T _cN$T _dN$T _dEBLCP _dYDX _dGW5XE _dNJR _dUAB _dIOG _dOCLCF _dCOO _dAZU _dUPM _dMERER _dESU _dOCLCQ _dJBG _dIAD _dICW _dICN _dOTZ _dOCLCQ _dU3W _dES-MaUEC _bspa
050		4	_aRD598.35.T7 _b2017 EB
245	0	0	_aClinical guide to heart transplantation _cJon Kobashigawa, editor.
264		1	_aCham, Switzerland _bSpringer International Publishing _c2017
264		4	_c2017
300			_a1 recurso en línea _bilustraciones (algunas a color)
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_atext file _bPDF _2rda
504			_aIncluye referencias bibliográficas e índice
505	0		_aIntroduction; Author Biography; Contents; Contributors; 1: Medical and€Device Options for€Patients with€End-Stage Heart Failure; Introduction; Medical and€Pharmacological Management of€End-Stage Heart Failure; Angiotensin Receptor-Neprilysin Inhibitors (ARNIs); Angiotensin-Converting Enzyme (ACE) Inhibitors and€Angiotensin Receptor Blockers (ARBs); Diuretics; Beta-Blockers; Ivabradine; Aldosterone-Receptor Antagonists; Hydralazine and€Isosorbide Dinitrate; Digoxin; Anticoagulation; Fluid Restriction; Inotropic Agents; Device Management of€End-Stage Heart Failure.
505	8		_aCardiac Resynchronization Therapy Implantable Cardioverter- Defibrillator (ICD); Further Options; Palliative Approaches to€Heart Failure; References; 2: Mechanical and€Surgical Options for€Patients with€End-Stage Heart Failure; Introduction; Ventricular Assist Device Categories: A€Generational History; Total Artificial Heart; Trends in€Ventricular Assist Device Use: Strategies and€Outcomes; Contraindications to€LVAD Insertion; INTERMACS Scale and€Risk Factors for€Mortality Post-implant; Potential Complications of€Left Ventricular Assist Devices.
505	8		_aLeft Ventricular Assist Device Selection Short Term Options for€Mechanical Circulatory Support; Intra-aortic Balloon Pump; Extracorporeal Membrane Oxygenation; Percutaneous Mechanical Circulatory Support; Cardiac Transplantation; References; 3: Evaluation for€Heart Transplant Candidacy; Introduction; Indications for€Cardiac Transplantation; Evaluation Testing; Cardiopulmonary Exercise Testing; Maximal Oxygen Consumption; Hemodynamic Performance Assessment; Heart Failure Survival Score (HFSS); The Seattle Heart Failure Model (SHFM); Other Factors.
505	8		_aOrgan Procurement Organizations Urgency-Based Tiers; Current Controversies in€Heart Allocation; The Future of€Heart Allocation: A€Further-Tiered System?; Optimization of€the€Pre-transplant Patient; Medical Surveillance on€the€Waitlist; Immunological Optimization; Other Considerations for€the€Wait-ƯListed Patient; Pre-operative Preparation of€the€Patient for€Transplantation; References; 5: Overview of€Transplantation Immunobiology; Innate Versus Adaptive Immunity; Overview and€Polymorphism of€HLA; Alloantigen Presentation/Cell Mediated Rejection.
505	8		_aPotential Contraindications to€Cardiac Transplantation Age; Obesity; Malignancy; Pulmonary Hypertension; Primary Pulmonary Disease; Diabetes Mellitus; Renal Dysfunction; Peripheral Vascular Disease; Frailty; Infections; HIV; Hepatitis B; Hepatitis C; Tuberculosis; Chagas Disease; Substance Use; Other Systemic Diseases; Psychosocial Evaluation; Financial Considerations; References; 4: Listing, Donor Allocation and€Optimization of€the Pre-Ưtransplant Patient; Introduction; Listing Process; Allocation Criteria; A Brief History; Current System.
520	3		_aThis handbook is an easy reference for those involved in the management of heart transplant. While this compilation of best practices cannot address the complexity of the individual patients we care for on a daily basis, it will serve to help us ask the right questions, access the best evidence and ultimately make the best decisions for the patients involved. Clinical Guide to Heart Transplantation provides a current review of the field of heart transplantation and how it has evolved into an established therapy for the treatment of end-stage heart failure. With the advent of improved surgical techniques, the development of immunosuppressive drugs and the utilization of more sophisticated monitoring strategies and treatments for graft rejection, heart transplantation now offer patients an avenue to both improved survival and quality of life. With over 4000 heart transplants performed per year globally and with 1-year survival approaching 90%, this practical title assists those involved in the this most complex of procedures to establish best practice. It is therefore essential reading for all practitioners in this field, charged with making critical decisions in the management of patients, donor organs, and the transplant process itself in order to achieve the greatest benefit in the utilization of this often scarce resource.
650		7	_9138127 _aCorazón _xTransplantation. _2fast _0(OCoLC)fst00953684 _0
700	1		_aKobashigawa, Jon A., _eeditor literario
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-43773-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
988			_aSpringer_Medicine_2017
998			_b02/2018 _dz _e- _zSI
999			_c95710 _d95710 _x1